ADAPT PHARMA

Lobbying Spend

—

Filings

Firms Hired

Active Period

2016–2018

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2018	—	2	1
2017	—	4	1
2016	—	5	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
DENTONS US LLP	—	11

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	3
SENATE	3

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	4

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 524114th Congress

Comprehensive Addiction and Recovery Act of 2016

2016 · third_quarter · Firm: DENTONS US LLP

Cited source text and reported amounts

Issues surrounding nasal Naloxone for emergency treatment of opioid overdose; S. 524, Comprehensive Addiction and Recovery Act (CARA)

Client expense: — · Firm income: $30,000

Matched citations: S. 524

S. 524114th Congress

Comprehensive Addiction and Recovery Act of 2016

2016 · second_quarter · Firm: DENTONS US LLP

Cited source text and reported amounts

Issues surrounding nasal Naloxone for emergency treatment of opioid overdose; S. 524, Comprehensive Addiction and Recovery Act (CARA)

Client expense: — · Firm income: $50,000

Matched citations: S. 524

ADAPT PHARMA — Lobbying Disclosure | Poliscope